Carbuncle

November 22nd 2024

Obesity & Type 2 Diabetes: An Expert Discussion

At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.

June 30th 2023

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

November 21st 2024

Respiratory Tripledemic 2022-23: An Expert Recap

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

April 6th 2023

Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Rises: Daily Dose

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.

Online Misinformation on UTIs, ASB is Common and Dangerous: New Research

Your daily dose of the clinical news you may have missed.

Related Content

November 22nd 2024

Obesity & Type 2 Diabetes: An Expert Discussion

At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.

June 30th 2023

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

November 21st 2024

Respiratory Tripledemic 2022-23: An Expert Recap

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

April 6th 2023

Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Rises: Daily Dose

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.